Lyra Therapeutics Inc. (LYRA) News
Filter LYRA News Items
LYRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LYRA News Highlights
- LYRA's 30 day story count now stands at 3.
- Over the past 9 days, the trend for LYRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DERM, ALPN and AUPH are the most mentioned tickers in articles about LYRA.
Latest LYRA News From Around the Web
Below are the latest news stories about LYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate LYRA as an investment opportunity.
4 Drug Stocks Rising More Than 40% in 2023 With Room to GrowNovo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024. |
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalAurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article. |
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New YearInnovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio. |
Lyra Therapeutics Insider Ups Holding By 11% During YearInsiders were net buyers of Lyra Therapeutics, Inc.'s ( NASDAQ:LYRA ) stock during the past year. That is, insiders... |
Executive Chairman of Lyra Therapeutics Harlan Waksal Buys 11% More SharesWhilst it may not be a huge deal, we thought it was good to see that the Lyra Therapeutics, Inc. ( NASDAQ:LYRA... |
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis (CRS) patients who have had prior ethmoid sinus surgery – – Emerging data further support the previously reported positive BEACON topline results demonstrating CRS symptom improvement – – ENLIGHTEN I pivotal Phase 3 trial of LYR-210 in CRS patients who have not had ethmoid sinus surgery is |
Lyra Therapeutics to Participate in Upcoming Investor ConferencesWATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in November: Jefferies London Healthcare Conference 2023 – Fireside chat on Thursday, November 16th at 1:30 p.m. GMTPiper Sandler 35th Annu |
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal OfficerWATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (“CRS”), today announced the appointment of Ronan O’Brien, as Chief Legal Officer, effective October 16, 2023. “We are pleased to welcome Mr. O’Brien to Lyra,” said Maria Palasis, Ph.D., Chief Executive Officer of Lyra. “His significant legal experience, in |
Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) market cap dropped US$20m last week; Private equity firms bore the bruntKey Insights Lyra Therapeutics' significant private equity firms ownership suggests that the key decisions are... |
Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock UpLyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery. |